- Home
- GALT vs PSF Comparison
GALT vs PSF Comparison
Compare GALT & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | PSF |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 229.1M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | PSF |
|---|---|---|
| Price | $2.68 | $19.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 319.4K | 41.1K |
| Earning Date | 03-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.69% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $17.93 |
| 52 Week High | $7.13 | $21.20 |
Technical Indicators
Market Signals| Indicator | GALT | PSF |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 52.62 |
| Support Level | $2.59 | $19.58 |
| Resistance Level | $3.32 | $19.90 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 15.75 | 100.00 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.